The Dedham Group

Direct-to-patient (DTP) models have moved well beyond early experimentation; they are now a central component of how pharma organizations think about commercialization. https://vist.ly/4tu4s In a new white paper, Chike Onyia and Manuel Jurado examine the rapid rise of DTP and outline three strategic considerations that pharma leaders must navigate as this channel matures. As manufacturers face evolving legislative pressures, competitive dynamics, and changing patient expectations, many are reassessing how—and how directly—they support patients across the access and fulfillment journey. Read the full white paper to see how leading manufacturers are shaping their DTP strategies and what it takes to execute effectively.

The energy at this year’s 44th Annual J.P. Morgan Healthcare Conference and Biotech Showcase was unmistakable. https://vist.ly/4r75h With sharper dealmaking, China’s rising biotech influence, AI proving real value, and next‑gen modalities advancing, one theme stood out: 2026 will belong to companies that execute with discipline and innovate with purpose. Click the link in this post to read the full recap, to explore the key takeaways, and what they mean for the biopharma industry.

Direct-to-patient (DTP) models are no longer a fringe experiment in pharma—they are rapidly becoming a core component of modern commercialization strategies. https://vist.ly/4qfxk In our latest white paper, Chike Onyia and Manuel Jurado explore the rise of direct-to-patient models and outline three strategic considerations for pharma leaders to succeed in this evolving channel. As manufacturers face increasing pressure from legislation, competitors, and patients, many are re-evaluating how—and how directly—they engage patients throughout the access and fulfillment journey. Read the full white paper to learn how leading manufacturers are approaching DTP—and what it takes to get it right.

Biotech Showcase and JPM Week officially begin today in San Francisco! The Dedham Group is excited to join industry leaders in collaborating on strategies to accelerate innovation and improve patient outcomes. Our focus remains on delivering actionable insights across commercial strategy, investor positioning, and market access for specialty therapeutics. If you’re attending, we’d love to connect. Say hello to our team on-site: • Sophia Xin Tan, PhD – Managing Partner • Sachin Purwar – Partner • Michael Hamlin – Associate Partner Let’s make this a high-impact start to the year. Reach out to schedule a conversation with our team. Details about the showcase: https://vist.ly/4mg9i Book a meeting with The Dedham Group: https://vist.ly/4mg9h

The Dedham Group is excited to join industry leaders in San Francisco during Biotech Showcase and JPM Week, from January 12-14, 2026! As the life sciences community comes together to shape the next wave of innovation, our team will be on the ground supporting clients and partners across: • Commercial Strategy Development — helping biopharma teams navigate evolving market dynamics, optimize go‑to‑market approaches, and accelerate patient impact. • Investor & Asset Value Story Development — supporting companies in positioning assets for fundraising and strategic transactions through clear, differentiated investor propositions grounded in clinical evidence and commercial readiness. • Investment Decision Support — providing evidence‑driven insights to guide pipeline prioritization, asset evaluation, and strategic capital allocation. • Specialty Therapeutics Market Access — delivering deep expertise across some of the most complex therapeutic areas. We look forward to connecting with biotech and pharma innovators, investors, and ecosystem partners to discuss how we can drive smarter, more strategic decisions in 2026 and beyond. If you’ll be in SF that week and would like to meet, explore collaboration, or simply catch up, we’d love to connect. Let’s make it a high‑impact start to the year. Details about the showcase: https://vist.ly/4m77k Book a meeting with The Dedham Group: https://vist.ly/4m78n

TOMORROW IS THE DAY! Register now: https://vist.ly/4dtmw Fierce Pharma and AssistRx are hosting an important conversation about patient access: How do we make sure patients receive life-changing therapies without delay? Join Rebecca Leemputte , Associate Partner at The Dedham Group, and Jordan Armstrong, Vice President, Business Development at AssistRx, as they share insights and strategies that matter. This discussion is happening tomorrow. Don’t miss it. Register now at the link in this post. Not sure if you can join live? Register anyway to receive the recording and watch when it’s convenient.

WEBINAR: How do we ensure patients get timely access to life-changing therapies? https://vist.ly/4dbff Fierce Pharma and AssistRx are hosting this important discussion featuring: • Rebecca Leemputte (Associate Partner at The Dedham Group) • Jordan Armstrong (Vice President of Business Development at AssistRx) They’ll explore: • Key policy shifts • Implications for patient access • Support strategies to address emerging challenges Register now at the link in this post. Can’t be there live? Register now and we’ll send you the recording so you can catch up anytime.

With the Inflation Reduction Act, Executive Orders, and state-level reforms accelerating change, life sciences organizations must rethink how they support patient access. Fierce Pharma and AssistRx are hosting this webinar where you’ll hear from experts, including Rebecca Leemputte , Associate Partner, The Dedham Group, and Jordan Armstrong, Vice President, Business Development, AssistRx, on the following topics: • The evolving policy landscape • Implications for patient affordability and access • How to elevate your support programs to meet new expectations Register here: https://vist.ly/4ctky If you can’t make it live, register today to get the post-event recording and view it on your schedule.